Annex VI to Regulation (EC) No 1272/2008 is amended as follows:
in Part 3, Table 3 is amended as follows:
the following entries are inserted:
Index No | Chemical Name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M- factors and ATE | Notes
Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)
‘014-052-00-7 | silanamine, 1,1,1-trimethyl-N-(trimethylsilyl)-, hydrolysis products with silica; pyrogenic, synthetic amorphous, nano, surface treated silicon dioxide | 272-697-1 | 68909-20-6 | STOT RE 2 | H373 (lungs) (inhalation) |
GHS08
Wng
H373 (lungs) (inhalation) | EUH066’ | |
‘035-005-00-7 | ammonium bromide | 235-183-8 | 12124-97-9 |
Repr. 1B
Lact.
STOT SE 3
STOT RE 1
Eye Irrit. 2
H360FD
H362
H336
H372 (nervous system)
H319
GHS08
GHS07
Dgr
H360FD
H362
H336
H372 (nervous system)
H319’
‘050-032-00-4 | dibutyltin bis(2-ethylhexanoate) | 220-481-2 | 2781-10-4 |
Muta. 2
Repr. 1B
STOT RE 1
H341
H360FD
H372 (immune system)
GHS08
Dgr
H341
H360FD
H372 (immune system)’
‘050-033-00-X | dibutyltin di(acetate) | 213-928-8 | 1067-33-0 |
Muta 2
Repr. 1B
STOT RE 1
H341
H360FD
H372 (immune system)
GHS08
Dgr
H341
H360FD
H372 (immune system)’
‘052-001-00-0 | tellurium | 236-813-4 | 13494-80-9 |
Repr. 1B
Lact.
H360Df
H362
GHS08
Dgr
H360Df
H362’
‘052-002-00-6 | tellurium dioxide | 231-193-1 | 7446-07-3 |
Repr. 1B
Lact.
H360Df
H362
GHS08
Dgr
H360Df
H362’
‘056-005-00-3 | barium diboron tetraoxide | 237-222-4 | 13701-59-2 |
Repr. 1B
Acute Tox. 4
Acute Tox. 3
H360FD
H332
H301
GHS08
GHS06
Dgr
H360FD
H332
H301
inhalation:
ATE = 1,5 mg/L (dusts or mists)
oral:
ATE = 100 mg/kg bw’
‘601-097-00-8 | Propylbenzene | 203-132-9 | 103-65-1 |
Flam. Liq. 3
Asp. Tox. 1
STOT SE 3
Aquatic Chronic 2
H226
H304
H335
H411
GHS02
GHS08
GHS07
GHS09
Dgr
H226
H304
H335
H411’
‘603-243-00-6 | 2,2-dimethylpropan-1-ol, tribromo derivative; 3-bromo-2,2-bis(bromomethyl)propan-1-ol | 253-057-0 | 36483-57-5; 1522-92-5 |
Carc. 1B
Muta. 2
H350
H341
GHS08
Dgr
H350
H341’
‘604-096-00-0 | piperonyl butoxide (ISO); 2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether | 200-076-7 | 51-03-6 |
STOT SE 3
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H335
H319
H400
H410
GHS07
GHS09
Wng
H335
H319
H410
EUH066 |
M = 1
M = 1’
‘604-097-00-6 | 2,4,6-tri-tert-butylphenol | 211-989-5 | 732-26-3 |
Repr. 1B
Acute Tox. 4
STOT RE 2
Skin Sens. 1B
H360D
H302
H373 (liver)
H317
GHS08
GHS07
Dgr
H360D
H302
H373 (liver)
H317
oral:
ATE = 500 mg/kg bw’
‘604-098-00-1 | 4,4'-sulphonyldiphenol; bisphenol S | 201-250-5 | 80-09-1 | Repr. 1B | H360FD |
GHS08
Dgr
H360FD’ | | |
‘606-153-00-5 | benzophenone | 204-337-6 | 119-61-9 | Carc. 1B | H350 |
GHS08
Dgr
H350’ | | |
‘606-154-00-0 | quinoclamine (ISO); 2-amino-3-chloro-1,4-naphthoquinone | 220-529-2 | 2797-51-5 |
Carc. 2
Repr. 2
Acute Tox. 4
STOT RE 2
Eye Irrit. 2
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1
H351
H361d
H302
H373 (blood system, kidneys)
H319
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H361d
H302
H373 (blood system, kidneys)
H319
H317
H410
oral:
ATE = 500 mg/kg bw
M = 10
M = 10’
‘607-756-00-6 | exo-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl acrylate; isobornyl acrylate | 227-561-6 | 5888-33-5 | Skin Sens. 1A | H317 |
GHS07
Wng
H317’ | | |
‘607-757-00-1 | daminozide (ISO); 4-(2,2-dimethylhydrazino)-4-oxobutanoic acid; N-dimethylaminosuccinamic acid | 216-485-9 | 1596-84-5 | Carc. 2 | H351 |
GHS08
Wng
H351’ | | |
‘607-758-00-7 | 4,4'-oxydi(benzenesulphonohydrazide) | 201-286-1 | 80-51-3 |
Self-react. D
Aquatic Acute 1
Aquatic Chronic 1
H242
H400
H410
GHS02
GHS09
Dgr
H242
H410
M = 1
M = 1’
‘607-759-00-2 | toluene-4-sulphonohydrazide | 216-407-3 | 1576-35-8 | Self-react. D | H242 |
GHS02
Dgr
H242’ | | |
‘607-760-00-8 | 2-[N-ethyl-4-[(5-nitrothiazol-2-yl)azo]-m-toluidino]ethyl acetate; C.I. Disperse Blue 124 | 239-203-6 | 15141-18-1 | Skin Sens. 1A | H317 |
GHS07
Wng
H317 | | Skin Sens. 1A; H317: C ≥ 0,001 %’ |
‘607-761-00-3 | Perfluoroheptanoic acid; tridecafluoroheptanoic acid | 206-798-9 | 375-85-9 |
Repr. 1B
STOT RE 1
H360D
H372 (liver)
GHS08
Dgr
H360D
H372 (liver)’
‘607-762-00-9 | methyl N-(isopropoxycarbonyl)-L-valyl-(3RS)-3-(4-chlorophenyl)-β-alaninate; valifenalate | - | 283159-90-0 |
Carc. 2
Aquatic Chronic 2
H351
H411
GHS08
GHS09
Wng
H351
H411’
‘607-763-00-4 | 6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid, sodium and tris(2-hydroxyethyl)ammonium salts | - | - |
Repr. 1B
Eye Irrit. 2
H360FD
H319
GHS08
GHS07
Dgr
H360FD
H319’
‘607-764-00-X | 6-[(C10-C13)-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid | - | 2156592-54-8 |
Repr. 1B
Eye Irrit. 2
H360FD
H319
GHS08
GHS07
Dgr
H360FD
H319’
‘607-765-00-5 | 6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid | - | - | Repr. 1B | H360FD |
GHS08
Dgr
H360FD’ | | |
‘613-341-00-0 | clofentezine (ISO); 3,6-bis(o-chlorophenyl)-1,2,4,5-tetrazine | 277-728-2 | 74115-24-5 | Aquatic Chronic 1 | H410 |
GHS09
Wng
H410 | | M = 1’ |
‘613-342-00-6 | theophylline; 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione | 200-385-7 | 58-55-9 | Repr. 1B | H360D |
GHS08
Dgr
H360D’ | | |
‘613-343-00-1 | pyridalyl (ISO); 2,6-dichloro-4-(3,3-dichloroallyloxy)phenyl 3-[5-(trifluoromethyl)-2-pyridyloxy]propyl ether | - | 179101-81-6 |
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H317
H400
H410
GHS07
GHS09
Wng
H317
H410
M = 1000
M = 100’
‘613-344-00-7 | Pyridine-2-thiol 1-oxide, sodium salt; pyrithione sodium; sodium pyrithione |
223-296-5;
240-062-8
3811-73-2;
15922-78-8
Acute Tox. 3
Acute Tox. 3
Acute Tox. 4
STOT RE 1
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 2
H331
H311
H302
H372 (nervous system)
H315
H319
H317
H400
H411
GHS06
GHS08
GHS09
Dgr
H331
H311
H302
H372 (nervous system)
H315
H319
H317
H410
EUH070 |
inhalation:
ATE = 0,5 mg/L (dusts or mists)
dermal:
ATE = 790 mg/kg bw
oral:
ATE = 500 mg/kg bw
M = 100’
‘613-345-00-2 |
1,3,5-triazine-2,4,6-triamine;
melamine
203-615-4 | 108-78-1 |
Carc. 2
STOT RE 2
H351
H373 (urinary tract)
GHS08
Wng
H351
H373 (urinary tract)’
‘615-046-00-2 | 1,3-bis(1-isocyanato-1-methylethyl)benzene; [m-TMXDI] | 220-474-4 | 2778-42-9 |
Resp. Sens. 1
Skin Sens. 1A
H334
H317
GHS08
Dgr
H334
H317’
‘615-047-00-8 | 1,3-bis(isocyanatomethyl)benzene; [m-XDI] | 222-852-4 | 3634-83-1 |
Resp. Sens. 1
Skin Sens. 1A
H334
H317
GHS08
Dgr
H334
H317
Skin Sens. 1A; H317: C ≥ 0,001 %’ |
‘615-048-00-3 | 2,4,6-triisopropyl-m-phenylene diisocyanate | 218-485-4 | 2162-73-4 |
Resp. Sens. 1
Skin Sens. 1
H334
H317
GHS08
Dgr
H334
H317’
‘615-049-00-9 |
1,5-naphthylene diisocyanate
[containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]
221-641-4 | 3173-72-6 |
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Resp. Sens. 1
Skin Sens. 1A
Aquatic Chronic 3
H335
H315
H319
H334
H317
H412
GHS07
GHS08
Dgr
H335
H315
H319
H334
H317
H412’
‘615-050-00-4 |
1,5-naphthylene diisocyanate
[containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]
221-641-4 | 3173-72-6 |
Acute Tox. 2
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Resp. Sens. 1
Skin Sens. 1A
Aquatic Chronic 3
H330
H335
H315
H319
H334
H317
H412
GHS06
GHS08
Dgr
H330
H335
H315
H319
H334
H317
H412
inhalation:
ATE = 0,27 mg/L (dusts or mists)’
‘616-237-00-3 | fluopicolide (ISO); 2,6-dichloro-N-[3-chloro-5-(trifluoromethyl)-2-pyridylmethyl]benzamide | - | 239110-15-7 | Repr. 2 | H361d |
GHS08
Wng
H361d’ | | |
‘616-238-00-9 | N-(2-nitrophenyl)phosphoric triamide | 477-690-9 | 874819-71-3 |
Repr. 1B
STOT RE 2
H360Fd
H373 (kidneys)
GHS08
Dgr
H360Fd
H373 (kidneys)’
‘616-239-00-4 | N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide; isoflucypram | - | 1255734-28-1 |
Repr. 2
Acute Tox. 4
Skin Sens. 1B
Aquatic Acute 1
Aquatic Chronic 1
H361f
H332
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H361f
H332
H317
H410
inhalation:
ATE = 2,2 mg/L (dusts or mists)
M = 10
M = 1’
‘616-240-00-X | Reaction mass of 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9RS)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide and 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9SR)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide [≥ 78 % syn isomers ≤ 15 % anti isomers relative content]; isopyrazam | - | 881685-58-1 |
Carc. 2
Repr. 1B
Skin Sens. 1B
Aquatic Acute 1 Aquatic Chronic 1
H351
H360D
H317
H400
H410
GHS08
GHS07
GHS09
Dgr
H351
H360D
H317
H410
Repr. 1B; H360D:
C ≥ 3 %
M = 10
M = 10’
‘650-058-00-1 | Margosa, ext. [from the kernels of Azadirachta indica extracted with water and further processed with organic solvents] | 283-644-7 | 84696-25-3 |
Repr. 2
Skin Sens. 1
Aquatic Chronic 1
H361d
H317
H410
GHS08
GHS07
GHS09
Wng
H361d
H317
H410
M = 10’ |
the entries corresponding to index numbers 014-001-00-9; 023-001-00-8; 601-024-00-X; 603-014-00-0; 603-107-00-6; 604-030-00-0; 607-111-00-9; 607-230-00-6; 607-253-00-1; 607-254-00-7; 607-734-00-6; 607-735-00-1; 607-736-00-7; 608-032-00-2; 609-042-00-X; 613-012-00-1; 616-164-00-7 are replaced by the following entries respectively:
Index No | Chemical Name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M- factors and ATE | Notes
Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)
‘014-001-00-9 | trichlorosilane | 233-042-5 | 10025-78-2 |
Flam. Liq. 1
Water-react. 1
Acute Tox. 3
Acute Tox. 4
Skin Corr. 1A
Eye Dam. 1
H224
H260
H331
H302
H314
H318
GHS02
GHS06
GHS05
Dgr
H224
H260
H331
H302
H314
EUH014
EUH029
EUH071
inhalation:
ATE = 7,6 mg/L (vapour)
oral:
ATE = 1000 mg/kg bw’
‘023-001-00-8 | divanadium pentaoxide; vanadium pentoxide | 215-239-8 | 1314-62-1 |
Muta. 2
Carc. 1B
Repr. 2
Lact.
Acute Tox. 3
Acute Tox. 2
STOT SE 3
STOT RE 1
Aquatic Chronic 2
H341
H350
H361fd
H362
H301
H330
H335
H372 (respiratory tract, inhalation)
H411
GHS06
GHS08
GHS09
Dgr
H341
H350
H361fd
H362
H301
H330
H335
H372 (respiratory tract, inhalation)
H411
inhalation:
ATE = 0,05 mg/L (dusts or mists)
oral:
ATE = 220 mg/kg bw’
‘601-024-00-X | Cumene | 202-704-5 | 98-82-8 |
Flam. Liq. 3
Carc. 1B
Asp. Tox. 1
STOT SE 3
Aquatic Chronic 2
H226
H350
H304
H335
H411
GHS02
GHS08
GHS07
GHS09
Dgr
H226
H350
H304
H335
H411’
‘603-014-00-0 | 2-butoxyethanol; ethylene glycol monobutyl ether | 203-905-0 | 111-76-2 |
Acute Tox. 3
Acute Tox. 4
Skin Irrit. 2
Eye Irrit. 2
H331
H302
H315
H319
GHS06
Dgr
H331
H302
H315
H319
inhalation:
ATE = 3 mg/L (Vapours)
oral:
ATE = 1200 mg/kg bw’
‘603-107-00-6 | 2-(2-methoxyethoxy)ethanol; diethylene glycol monomethyl ether | 203-906-6 | 111-77-3 | Repr. 1B | H360D |
GHS08
Dgr
H360D | | Repr. 1B; H360D: C ≥ 3 %’ |
‘604-030-00-0 | 4,4'-isopropylidenediphenol; bisphenol A | 201-245-8 | 80-05-7 |
Repr. 1B
STOT SE 3
Eye Dam. 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H360F
H335
H318
H317
H400
H410
GHS08
GHS07
GHS05
GHS09
Dgr
H360F
H335
H318
H317
H410
M = 1
M = 10’
‘607-111-00-9 |
2-ethyl-2-[[(1-oxoallyl)oxy]methyl]-1,3-propanediyl diacrylate; 2,2-bis(acryloyloxymethyl)butyl acrylate;
trimethylolpropane triacrylate
239-701-3 | 15625-89-5 |
Carc. 2
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H351
H315
H319
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H315
H319
H317
H410
M = 1
M = 1
D’
‘607-230-00-6 | 2-ethylhexanoic acid and its salts, with the exception of those specified elsewhere in this Annex | - | - | Repr. 1B | H360D |
GHS08
Dgr
H360D’ | | |
‘607-253-00-1 | cyfluthrin (ISO); α-cyano-4-fluoro-3-phenoxybenzyl-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate | 269-855-7 | 68359-37-5 |
Lact.
Acute Tox. 2
Acute Tox. 2
STOT SE 1
Aquatic Acute 1
Aquatic Chronic 1
H362
H330
H300
H370 (nervous system)
H400
H410
GHS06
GHS08
GHS09
Dgr
H362
H330
H300
H370 (nervous system)
H410
inhalation:
ATE = 0,14 mg/L (dusts or mists)
oral:
ATE = 14 mg/kg bw
M = 1000000
M = 1000000’
‘607-254-00-7 | beta-cyfluthrin (ISO); reaction mass of rel-(R)-cyano(4-fluoro-3-phenoxyphenyl)methyl (1S,3S)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate and rel-(R)-cyano(4-fluoro-3-phenoxyphenyl)methyl (1S,3R)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate | - | 1820573-27-0 |
Lact.
Acute Tox. 2
Acute Tox. 2
STOT SE 1
Aquatic Acute 1
Aquatic Chronic 1
H362
H330
H300
H370 (nervous system)
H400
H410
GHS06
GHS08
GHS09
Dgr
H362
H330
H300
H370 (nervous system)
H410
inhalation:
ATE = 0,081 mg/L (dusts or mists)
oral:
ATE = 11 mg/kg bw
M = 1000000
M = 1000000’
‘607-734-00-6 | pentapotassium 2,2',2",2"',2""-(ethane-1,2-diylnitrilo)pentaacetate | 404-290-3 | 7216-95-7 |
Repr. 1B
Acute Tox. 4
STOT RE 2
Eye Irrit. 2
H360D
H332
H373 (inhalation)
H319
GHS08
GHS07
Dgr
H360D
H332
H373 (inhalation)
H319
Repr. 1B; H360D: C ≥ 3 %
inhalation:
ATE = 1,5 mg/L (dusts or mists)’
‘607-735-00-1 | N-carboxymethyliminobis(ethylenenitrilo)tetra(acetic acid) | 200-652-8 | 67-43-6 |
Repr. 1B
Acute Tox. 4
STOT RE 2
Eye Irrit. 2
H360D
H332
H373 (inhalation)
H319
GHS08
GHS07
Dgr
H360D
H332
H373 (inhalation)
H319
Repr. 1B; H360D: C ≥ 3 %
inhalation:
ATE = 1,5 mg/L (dusts or mists)’
‘607-736-00-7 | pentasodium (carboxylatomethyl)iminobis(ethylenenitrilo)tetraacetate | 205-391-3 | 140-01-2 |
Repr. 1B
Acute Tox. 4
STOT RE 2
H360D
H332
H373 (inhalation)
GHS08
GHS07
Dgr
H360D
H332
H373 (inhalation)
Repr. 1B; H360D: C ≥ 3 %
inhalation:
ATE = 1,5 mg/L (dusts or mists)’
‘608-032-00-2 | acetamiprid (ISO); (1E)-N-[(6-chloropyridin-3-yl)methyl]-N’-cyano-N-methylethanimidamide; (E)-N1-[(6-chloro-3-pyridyl)methyl]-N2-cyano-N1-methylacetamidine | - | 135410-20-7 160430-64-8 |
Repr. 2
Acute Tox. 3
Aquatic Chronic 1
Aquatic Acute 1
H361d
H301
H410
H400
GHS08
GHS06
GHS09
Dgr
H361d
H301
H410
oral:
ATE = 140 mg/kg bw
M = 10
M = 10’
‘609-042-00-X | pendimethalin (ISO); N-(1-ethylpropyl)-2,6-dinitro-3,4-xylidene | 254-938-2 | 40487-42-1 |
Repr. 2
Aquatic Acute 1
Aquatic Chronic 1
H361d
H400
H410
GHS08
GSH09
Wng
H361d
H410
M = 100
M = 10’
‘613-012-00-1 | bentazone (ISO); 3-isopropyl-2,1,3-benzothiadiazine-4-one-2,2-dioxide | 246-585-8 | 25057-89-0 |
Repr. 2
Acute Tox. 4
Eye Irrit. 2
Skin Sens. 1
H361d
H302
H319
H317
GHS08
GHS07
Wng
H361d
H302
H319
H317
oral: ATE = 1600 mg/kg bw’ |
‘616-164-00-7 | dimoxystrobin (ISO); (2E)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-(methoxyimino)-N-methylacetamide; (E)-2-(methoxyimino)-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide | | 149961-52-4 |
Carc. 2
Repr. 2
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
H351
H361d
H332
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H361d
H332
H410
inhalation:
ATE = 1,3 mg/L (dusts or mists)
M = 100
M = 100’
the entry corresponding to index number 615-007-00-X is deleted.